Factors influencing the prescription of first-line treatment for type 2 diabetes 1

mellitus: a systematic review 2

Helena	Moreira ^{1,2*} Fernando Moreira ³ Ângelo Jesus ³ Matilde Monteiro-Soares ^{1,4,5,7} Paulo Santos ^{1,6}
1.	MEDCIDS – Department of Community Medicine, Information and Health Decision Sciences, Faculty
	Medicine of the University of Porto, Porto, Portugal
2.	Escola Superior de Saúde, Instituto Politécnico do Porto, Porto, Portugal
3.	REQUIMTE/LAQV, Escola Superior de Saúde, Instituto Politécnico do Porto, Rua Dr. António
	Bernardino de Almeida, 4200-072 Porto, Portugal
4.	Escola Superior de Saúde da Cruz Vermelha Portuguesa – Lisboa, Lisbon, Portugal
5.	CrossI&D: Lisbon Research Center, Escola Superior de Saúde da Cruz Vermelha Portuguesa - Lisbo
	Lisbon, Portugal
6.	RISE@CINTESIS: Center for Health Technology and Services Research, Faculty of Medicine Opor
	University, Porto, Portugal
* Corre	esponding author
E-mail	: <u>up201500208@edu.med.up.pt</u>
A 1	
A	DSTRACT
	Helena 1. 2. 3. 4. 5. 6. * Correc E-mail

Introduction 20

21 Understanding and predicting prescription preferences for type 2 diabetes mellitus, a heterogeneous and 22 complex condition that affects over 10% of the global adult population, can improve prescribing practices, 23 guide policymakers in promoting evidence-based medicine, and help tailor first-line treatments to individual 24 characteristics or specific subgroups, improving patient outcomes. This study aimed to identify factors 25 influencing metformin prescription, the first-line therapy recommended in Western guidelines, and to assess 26 factors leading to its avoidance and their alignment with evidence-based medicine. It also explores factors

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

associated with initial combination therapy, a newer and controversial approach compared to stepwisetherapy.

29

30 Methods

We performed a systematic search in PubMed, Scopus and Web of Science for observational analytical studies evaluating factors associated with metformin or combination therapy initiation. Quality assessment was done using the Joanna Briggs Institute critical appraisal checklists. (PROSPERO registry number <u>CRD42023438313</u>).

35

36 **Results**

Thirty studies were included, evaluating 105 variables, mostly (62%) assessed in one study. The 25 variables using combination therapy as outcome were mostly (72%) evaluated also in one study. Initial metformin prescription was strongly associated with the age of individuals with diabetes, glycated haemoglobin levels, body mass index, and renal complications, while combination therapy was mainly linked with glycated haemoglobin levels and comorbidities. Findings also highlighted a discrepancy between clinical practice and evidence-based recommendations. However, concerns were raised regarding both the internal and external validity of the included studies.

44

45 **Conclusion**

46 Our systematic review, that offers insights into real-world clinical practices, indicated that there is a 47 misalignment between clinical practices and evidence-based recommendations supporting the need for 48 interventions of this field.

49

50 Keywords

clinical decision-making, combination therapy, first line, metformin, prescribing, type 2 diabetes mellitus.

Introduction 54

55 More than 90% of people with diabetes have type 2 diabetes mellitus (T2DM), which is a chronic 56 complex disease, and management requires a multifactorial approach to prevent or delay microvascular and 57 macrovascular complications [1]. With a global prevalence of 10.5% among individuals aged 20 to 79 in 58 2021 [2], T2DM contributes to 11.3% of deaths worldwide [3]. It has led to a 315% increase in healthcare 59 expenditures over 15 years (2007-2021) [2], significantly burdening healthcare systems and society.

60 Several classes of antidiabetic drugs (ADs) are currently available, each with distinct profiles of 61 effectiveness and safety [4]. The most commonly used ADs belong to seven drug groups: biguanides, 62 sulfonylureas (SU), thiazolidinediones (TZDs), dipeptidyl peptidase-4 inhibitors (DPP4i), sodium-glucose 63 transporter-2 inhibitors (SGLT2i), glucagon-like peptidase receptor-1 agonists (GLP1-RA) and insulins [5]. Metformin (biguanide) is a unanimous recommendation as first-line in Western guidelines [4, 6, 7]. However, 64 65 the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) 66 acknowledge that alternative first-line treatments may be appropriate. Specifically, SGLT2i and GLP1-RA 67 are recommended for individuals with established cardiovascular disease, high cardiovascular risk, heart 68 failure, or chronic kidney disease (CKD), irrespective of metformin use. Further, they also suggest initial 69 combination therapy (i.e., starting with two or more drugs) when the glycated haemoglobin (HbA1c) is 1.5% 70 above the target at diagnosis (i.e., >70 mmol/mol [>8.5%]) [4]. Therefore, with multiple therapeutic options 71 available for treating this complex chronic disease, selecting the appropriate drug(s) can be a challenge for 72 physicians.

73 Variation in healthcare resources and utilization raises essential questions about resource allocation 74 quality, equity, and efficiency, with significant implications for healthcare and health policy [8]. Such 75 variation is more likely to occur when multiple treatment options are available, leading to uncertainty about 76 the most appropriate clinical choice, a phenomenon known as "professional uncertainty" [9]. Given that 77 diabetes is a complex medical condition with diverse clinical manifestations and varying treatment 78 responses, variations related to clinical conditions and individual preferences are expected. However, how 79 much of this variation can be attributed to factors other than differences in individual health status or 80 preferences?

81 A systematic review that approaches factors influencing first-line choice decisions in T2DM has yet to be found. Such a review would offer a more comprehensive perspective on potential factors and 82 83 demonstrate the robustness of scientific evidence in this field. Further, identifying the factors can reveal possible clinical variations and lead to actions that promote more evidence-based medicine and increase 84 85 equity in healthcare. Given that metformin is the recommended first-line treatment in guidelines and that 86 combination therapy, which may include metformin, is a newer approach, this systematic review aims to 87 summarize the key predictors for prescribing metformin or combination therapy as the first-line treatment for T2DM. 88

89

90 Material and Methods

This systematic review strictly adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [10] and was duly registered in the PROSPERO database in July 2023 under <u>CRD42023438313</u>. The protocol registered in PROSPERO outlines a more comprehensive systematic review, part of which is presented here.

95

96 Search strategy

97 A search was conducted in Medline (PubMed), Scopus and Web of Science on August 25, 2023, without 98 language or time restrictions. With the clinical question (PECO-S) formulated, the search strategy was 99 developed, with the Population (individuals with T2DM drug-naïve), Exposure (predictive factors), 100 Outcome (starting metformin or combination therapy), and type of Study (observational analytical studies). 101 The search strategy combined medical subject headings, free terms, and terms in the title/abstract, and it is 102 available in S1, S2, and S3 Tables. Further, the references of relevant articles were manually searched for 103 potentially eligible studies, and experts were also consulted. The grey literature was searched through 104 ProQuest, Networked Digital Library of These and Dissertations, Eldis, and targeted websites like the 105 World Health Organization (WHO), the United Nations, the International Diabetes Federation, the New 106 York Academy of Medicine, and the National Institutes of Health.

Inclusion and exclusion criteria 108

109 The inclusion and exclusion criteria were selected based on the PECO-S elements, and all details are

- 110 shown in Table 1.
- 111

Table 1: Study inclusion and exclusion criteria.

Category	Inclusion criteria
Study population	At least 80% adults (≥18 years old) with T2DM and naïve to antidiabetic medications or subgroup analysis provided.
	All factors that can influence prescribing, such as physician-related factors, patient-related factors, healthcare
Expose/Exhibit	system-related factors, influence of pharmaceutical companies and cost.
	The choice of first-line oral antidiabetic therapy: metformin (a biguanide) or combination therapy (i.e.,
Outcomes	starting with two or more drugs simultaneously).
Publication type	Observational analytical studies.
Category	Exclusion criteria
Study population	Studies on pregnant or breastfeeding women.

112

Study selection 113

114 EndNote 20® was used to manage references and identify duplicates. After that, the Rayyan QCRI [11] 115 tool was employed to allow two researchers (MH and MF or JA) to blindly and independently select the references for this systematic review. Titles and abstracts were screened in the first stage, with any 116 disagreements between researchers leading to studies being transferred to the second stage. In the second 117 118 stage, the full text was analysed. Disagreements were resolved by consensus; a third researcher was consulted 119 if a consensus was not reached. This procedure was done for study selection, data extraction and risk of 120 bias analysis. The agreement proportion between the two reviewers was calculated for each stage.

121

Data extraction 122

123 Data were extracted by MH and confirmed by MF or JA following previously determined variables: (1) 124 study identification (title, author(s), publication year, and country), (2) methods (sources and methods of 125 participants selection, inclusion and exclusion criteria, sample size and its characteristics (gender and mean age), period(s) of data collection, follow-up, setting, statistical analysis methods, and potential bias), (3) 126 127 outcomes analysed and their prevalence, list of variables (factors) and degree of statistical significance 128 associated with the outcomes.

129

Risk of bias and data analysis 130

Two independent reviewers (MH and MF or JA) assessed the quality of studies using the Joanna Briggs 131

132 Institute (JBI) quality assessment checklist for cross-sectional and cohort studies[12].

133 Due to the expected and observed high heterogeneity of studies, a meta-analysis was not feasible. Instead,

a narrative synthesis occurred to map all predictive factors influencing metformin or combination therapy 134

135 as a first-line choice. The criterion for a statistically significant association between exposure and outcomes

was p-value <0.05, or a 95% confidence interval that did not include 1 in studies where the association was 136

reported through risk measures (relative risk, odds ratio or hazard ratio). 137

138

Results 139

Study selection 140

Fig 1 presents the selection process flowchart providing the main reasons for exclusion. Initially, 1,645 141 142 studies were identified, and four additional studies were found through reference reviews of the included 143 studies. In the end, after two stages of screening studies, 30 studies were included. The proportion of 144 agreement between the independent assessors from the first and second stages of screening studies was 51.4% and 69.5%, respectively. 145

146

Fig 1: Flowchart of study selection 147

Study characteristics 148

149 Tables 2 and 3 presents the characteristics of the included studies. Considering the study design, 9 (30%)

[13–21] were retrospective cohort studies and 21 (70%) [22–42] were cross-sectional studies. Most studies 150

were from Europe (n=12 (40%)), North America (n=11 (36.7%)), with only 6 (20%) being from Asia and 151

1 (3.3%) from Australia. The number of participants varied widely, ranging from 415 to 1,136,723, with a 152

153 median of 27,138.

Study and country	Pa cha	rticipant racterist	is' ics	Period to identify sample	Follow- up	Source of data	Setting	Antidiabe	tic drug studied
	Sample	Male (%)	Mean Age (years)	_	(months)				Prevalence initiation (%)
Retrospective coho	rt studies								
Brouwer <i>et al.</i> (2012) [13], US	1972	48	>21	Jan 98 to Mar 09	Vary*	Vendor-based electronic health records (from BHCS and CCHS)	Primary care	Metf vs. SU (ref.) Metf vs. TZDs (ref.) Metf vs. CT (ref.) SU vs. CT (ref.)	66.63 (M) 10.60 (S) 5.22 (T) 13.74 (CT)
Zhang <i>et al.</i> (2012)[14], US	10743	45	61	Jan 03 to Dec 05	24	General Electronic Healthcare's Clinical Data Services electronic medical record database	Multicentre	Metf	64 (M)(<65years) ¹ 49 (M) (≥65years) ¹
Sinclair <i>et al.</i> (2012)[15], UK	9158	54	62	Jan 03 to Dec 05	24	International Medical Statistics (IMS) MediPlus database	Information from general practitioners.	Metf	76 (M) ¹
Raebel <i>et al.</i> (2013)[16], US	241327	53	59	Jan 05 to Dec 10	6	Surveillance Prevention and Management of diabetes mellitus (SUPREME-DM)	Multicentre	SU vs. Metf (ref.)	19,17 (S) ¹ 65.53 (M) ¹
Geier <i>et al.</i> (2014)[17], Germany	27138	49	63	Jun 03 to Dec 09	Vary*	German Disease Management Program for T2DM (DMP-DM2), funding by health insurance	Multicentre	Metf vs. SU (ref.)	33 (M) ² 7 (S) ²
Wright (2014) [18], UK	44838	57	61	Jan 05 to Dec 09	Vary*	Clinical Practice Research Datalink	Primary care	SU vs. Metf (ref.)	10.4 (S) 87.8 (M)
Li (2019)[19], US	231408	38	72	Jan 07 to Dec 17	12	Health insurance database (Medicare)	Multicentre	Metf Metf vs. SU (ref.)	68.4 (M) ¹ 14.8 (S) ¹
Carrillo Balam (2020) [20], Scotland	154660	56	61	Jan 04 to Dec 12	24	Scottish care information – diabetes	Multicentre	Metf	82.3 (M)
Ouchi <i>et al.</i> (2023)[21], Spain	86854	58	59	Jan 15 to Dec 20	Vary*	Electronic medical records from SIDIAP	Primary care	MT vs. MT	78.3 (MT) 21.7 (CT)

155 Studies are listed in chronological order, from the oldest to the most recent.

156 US, the United Stated of America; UK, the United Kingdom; BHCS, Baylor Health Care System; CCHS, Christiana Care Health System; SIDIAP, Information System for Research in Primary Care;

Metf (M), metformin; SU (S), Sulfonylureas; TZDs (I), Thiazolidinediones; MT, monotherapy; CT, combination therapy which means exposure to ≥ 2 or more drugs, CT in Brouwer *et al.* [13] include only metformin, sulfonylureas and thiazolidinedione; vs., versus meaning that one drug was compared to another in statistical analysis; (ref.), category used as a dependent variable reference in statistical analysis;

160 *Follow-up definitions: Brouwer et al. [13] followed patients until the first of the date of their last documented visit in the electronic health records plus 18 months or to 7 July 2009; In Geier et al. [17]

161 the follow-up happened until individuals were started on antidiabetic drug therapy, death, or study end date, whichever came first; Wright [18] followed individuals from their identification (at any time

162 during the sample identification period) until the end of the study (December 2012); Ouchi *et al.* [21] followed patients for at least 12 months or until death, or end of data availability (transferred to another database or December 2020).

164 ¹Prevalence among those who initiated therapy (not all of the sample initiated therapy). ²The prevalence in Geier *et al.* [17] was calculated for the entire sample, among those who initiated therapy and those who did not.

166 those who u

Study and country	y Participants' Period to Source of data characteristics identify sample		Source of data	Setting	Antidiabetic o	drug studied		
	Sample size	Male (%)	Mean Age (years)	-				Prevalence initiation (%)
Cross-sectional studies								
Winkelmayer <i>et al.</i> (2011) [22], Austria	39077	50	63	Jan 06 to Jun 08	Insurance claims data (public and non-for-profit health insurance company)	Multicentre	Metf vs. AHA (ref.)	71.7 (M)
Desai <i>et al.</i> (2012) [23], US	254973	53	58	Jan 06 to Dec 08	Prescription claims data from CVS Caremark	Multicentre	Metf Metf vs MT (ref.)	51 (M)
Grimes <i>et al.</i> (2014)[34], Ireland	20947	58	>40	Jan 08 to Dec 09	National pharmacy claims databases in Ireland ⁴	Multicentre	Metf vs. MT	76 (M)
Abdelmoneim <i>et al.</i> (2013)[36], Canada	39276	NR	≥66	Jan 98 to Dec 10	Alberta Blue Cross provincial insurance program	Multicentre	Metf vs. SU (ref.)	84.2 (M, 2010) 4.5 (S, 2010)
Wang <i>et al.</i> (2013)[37], Canada	1279	49	≥18	Jan 03 to Dec 11	Electronic health record (MOXXI: Medical Office of the XXIst Century)	Primary care	SU vs. Metf* (ref.) TZDs vs. Metf* (ref.) Metf* vs. AHA (ref)	92 (M*)
Mitchell <i>et al.</i> (2013) [38], US	4627	48	53	Jan 06 to Jun 10	The i3 Invision Data Mart database (OptumInsight, Eden Prairie, MN, US)	Multicentre	CT, Metf	93.24 (MT)
Vashisht <i>et al.</i> (2016)[39], US	6121	51	NR	NR	Electronic medical records from Stanford Clinical Data Warehouse	Hospital	Glipizide vs. Metf (ref.) Pioglitazone vs. Metf (ref.)	NR
Fujihara <i>et al.</i> (2017)[40], Japan	2666	64	61	Dec 09 to Mar 15	The Japan Diabetes Clinical Data Management Study Group (JDDM)	Outpatient clinics (clinical diabetologists)	Metf vs. SU (ref.)	35.7 (M) 11.4 (S)
Tanabe <i>et al.</i> (2017)[41], Japan	7108	63	NR	Apr 08 to Apr 13	Electronic information systems constructed by Medical Data Vision (MDV)	Multicentre	SU vs. Metf	18.4 (S) 26.5 (M)
Liu <i>et al.</i> (2017)[42], Taiwan	28640	53	57	Jan 06 to Dec 10	Taiwan National Insurance Research Database	Multicentre	AHA vs. Metf*(ref.)	43.8 (AHA, 2006) 26.2 (AHA, 2010)
Morita <i>et al.</i> (2019)[24], Japan	224761	61	66	Oct 12 to Sept 16	Medical Data Vision database, a Diagnosis Procedure Combination database	Outpatient	DPP4i vs. Metf (ref.)	26.2 (D) 7.1(M)
Pinto <i>et al.</i> (2019)[25], Portugal	415	55	NR	Jan 14 to Dec 15	Portuguese Sentinel Practice Network	Multicentre	Metf, CT.	85.5 (M) 6.5 (CT)
Juste et al. (2019)[26], Italy	14679	55	64	Jan 16 to Dec 16.	Campania Regional Database for Medication Consumption	Primary care	MT vs. CT	86.9(MT) 13.1(CT)
Moreno-Juste <i>et al.</i> [27] (2020), Spain	4247	58	65	Oct 13 to Sep 14	Electronic health records and pharmacy billing records from health system (EpiChron Cohort)	Multicentre	Metf MT vs. CT	80.5 (M) 88.7(MT) 11.3 (CT)

Study and country	Participar	nts' charac	cteristics	Period to identify sample	Source of data	Setting	Antidiabetic drug stu	ıdied
	Sample size	Male (%)	Mean Age (years)	_				Prevalence initiation (%)
Cross-sectional stu	idies							
Yabe <i>et al.</i> (2020)[28], Japan	1485	62	60	Jun 16 to May 19	Real-world observational study on patient outcomes in Diabetes (RESPOND)	Multicentre	Metf	16 (M)
Wood <i>et al.</i> (2020) [29], Australia	47860	53	61	Jul 13 to Feb 18.	Random sample from Australia's Pharmaceutical Benefits Scheme	Multicentre	SU vs. Metf (ref.) Non-Metf vs. Metf (ref.) CT vs. Metf (ref.)	85.8 (M) 4.6 (S) 1.9 (Non - M) 7.7 (CT)
Campbell <i>et al.</i> (2021) [30], Canada	17932	55	56	Apr 12 to Mar 17	Multiple administrative health datasets from Alberta, Canada	Multicentre	AHA ⁵ vs. Metf (ref.)	89 (M)
Shin et al. (2021)[31],	264542	55	59	April 13 to Dec	Health insurance databases (Optum Clinformatics	Multicentre	Metf	Last data
US	(Clinf.)	(Clinf.)	(Clinf.)	19 (Clinf.)	(Clinf.) and Medicare fee-for-service (Med.))		Drugs without cardiovascular	available:
	285213	46	73	April 13 to Dec			benefits vs. Metf (ref.)	83,1 (M, Clinf.)
	(Med)	(Med.)	(Med.)	17 (Med.)			Drugs With cardiovascular benefits benefits vs. Metf (ref.)	80.6 (M,. Med.)
Bonora <i>et al.</i> (2021) [32], Italy	65932	51	NR	Jan 18 to Dec 18	Administrative data from National Health System (ARNO Diabetes Observatory database)	Multicentre	Metf, CT	71.9 (M) 3.8 (CT)
Barth <i>et al.</i> (2022) [33], Germany	16006	57	61	Jan 15 to Dec 20	Health care database (Disease Analyzer database (IQVIA))	Multicentre	Metf	77 (M)
Bouchi <i>et al.</i> (2022)[35], Japan	1136723	58	>20	Oct 14 to Mar 18	National Database of health Insurance Claims and Specific Health Chek-ups in Japan	Outpatient clinic	Metf vs. MT (ref.)	15.9 (M)

Table 3 (continued)

171 Studies are listed in chronological order, from the oldest to the most recent;

172 NR, not reported; US, the United Stated of America; UK, the United Kingdom; ⁴From the General Medical Services (GMS) scheme and the Long-Term Illness (LTI) scheme;

173 174 Metf (M), metformin; Non-Metf (Non-M), non-metformin include acarbose, thiazolidinediones, dipeptidase-4 inhibitors, glucagon-like peptidase receptor-1 agonists or sodium-glucose

175 transporter-2 inhibitors; SU (S), Sulfonylureas; TZDs (I), Thiazolidinediones; DPP4i (D), dipeptidyl peptidase-4 inhibitors; MT, monotherapy; CT, combination therapy which means exposure to ≥2 or

176 more drugs, CT in Brouwer et al. [13] include only metformin, sulfonylureas and thiazolidinedione; AHA, other oral antihyperglycemic agents (it can include monotherapy and combination therapy); 177

Drugs without cardiovascular benefits include sulfonylureas, dipeptidyl peptidase-4 inhibitors, thiazolidinedione and others (alpha-glucosidase inhibitors, amylin mimetics, dopamine receptor agonists and

178 meglitinides); Drugs with cardiovascular benefits include sodium-glucose cotransporte-2 inhibitors and glucagon-like peptide-1; vs., versus meaning that one drug was compared to another in statistical

179 analysis; (ref.), category used as a dependent variable reference in statistical analysis; *alone or in combination therapy; ⁵It included metformin in combination therapy;

81 Twenty studies employed data from multicentre settings [14, 16, 17, 19, 20, 22, 23, 25, 27-34, 36, 38, 41, 42] and six studies 82 from primary care or general practitioners [13, 15, 18, 21, 26, 37]. All studies relied on secondary data, defined as data collected by others for purposes different from the objectives of the research, such as medical records and healthcare billing files[43]. 83 84 Twenty-eight studies [13–20, 22–25, 27–42] explored factors associated with metformin initiation. Nineteen [13, 16–19, 22– 24, 29-31, 34-37, 39-42] of these studies employed statistical models that examined factors linked to metformin initiation in 85 86 direct comparison to initiation of other antidiabetic drug(s). Sulfonylureas group were the most frequently compared drugs, accounting for 36.7% (n=11) of these studies [13, 16–19, 29, 36, 37, 39–41]. Eight studies [13, 21, 25–27, 29, 32, 38] examined 87 factors influencing combination therapy initiation, and 6 studies [13, 25, 27, 29, 32, 38] analysed metformin and combination 88 89 therapy in the same study.

90

Data extracted and analysed

The 105 variables extracted from the thirty studies are categorized into four main groups of factors: physician (Table 4), healthcare system (Table 5), patient (Tables 6, 7 and 8), and disease factors (Table 9). The most extensive group of factors belongs to patient factors, with five subgroups of factors recognised: sociodemographic, lifestyle and metabolic, cardiovascular, renal and other clinical factors. Sixty-five variables (62%) were evaluated by one study, and 11 (10,5%) were assessed by five or more studies.

It is also important to highlight that one study [31] showed data analysis not as a single block, but for different periods and two databases, and another [42] employed two statistical analyses: multivariable logistic regression and multilevel linear model.

99

Table 4: Strength of association between physician-related factors with the outcomes.

Physician-related factors	Outcomes											
		Metf.	W/CVB	WCVB	AHA	СТ						
Age (cat.)	Metf.				+++[22]							
					++[42]							
Years of experience (cont.)	Metf.				[37]							
Gender	Metf.				++[42] ^{LR}							
					[22]							
					[37][42] ^{ML}							
Medicine evidence questionnaire (cat.)	Metf.				[37]							
Physician Speciality	Metf.		++ [31]	++ [31]	+++[22]							
					++[42][30]							
		+[28]				+[25]						
		-[25]										

+++, variable with statistically significant association with the outcome in both univariable and multivariable analyses; ++, variable with statistically significant association with the outcome only in multivariable analysis; +, variable with statistically significant association with the outcome only in univariable analysis; - - -, variable with no statistically significant association with the outcome in both univariable and multivariable analyses; - -, variable with no statistically significant association with the outcome in multivariable analyses -, variable with no statistically significant association with the outcome only in univariable analyses; - - , variable with the outcome only in univariable analyses; - - , variable with the outcome only in univariable analyses;

Metf., metformin; W/CVB, drugs without cardiovascular benefits (sulfonylureas, dipeptidyl peptidase-4 inhibitor, thiazolidinediones, α-glucosidase inhibitors, amylin mimetics agents, dopamine receptor agonists, and meglitinides); WCVB, drugs with cardiovascular benefits (Sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists); AHA, other antidiabetic agents can include monotherapy or combination therapy; CT, combination

08 therapy; cont., continuous; cat., categorical;

09 Statistical analysis used: LRData from logistic regression [42], ^{ML}Data from multilevel model [42];

Table 5: Strength of association between healthcare system-related factors with outcomes.

<u>Healthcare system-related factors</u>	Outcomes										
		Metf.	SU	DPP4i	W/CVB	WCVB	MT	AHA			
Guidelines (updates)	Metf.		[37]					++ [37]			
	TZDs	++[37]									
Time (cont.)	Metf.		++[36]				++ [23]				
		$+[19][23][31]^{1}$									
		-[31] ²									
Time (cat.)	Metf.		+++[16]				++[29][35]	+++[22]			
			++[17][29]					++ [42]			
			[13]								
	TZDs	++[13]									
	СТ	++[29]	[13]								
		[13]									
HbA1c tests (cat.)	Metf.				++[31]	++[31]					
Office visits (cont.)	Metf.		+++[36]	+[24]	[31]	++[31]ALX					
						[31] ^{2(TB)}					
Hospitalisation (cont.)	Metf.		+[36]								
			[36]								
Hospitalisation (cat.)	Metf.		++[19]		++[31]	++[31]ALX					
						[31] ^{1(TB),2(TB)}					
Length of hospital stay (cont.)	Metf.				$++[31]^{2(TB,TC)}$	$++[31]^{2(TA)}$					
					[31] ^{ALX}	[31] ^{ALX}					
Length of hospital stay (cat.)	Metf.							+++[22]			
Emergency visits (cont.)	Metf.		+[36]								
			[36]								
Emergency visits (cat.)	Metf.				[31]	$++[31]^{ALX}$					
						[31] ^{1(TA)}					
Preventive healthcare service	Metf.				++[31]	++[31] ^{2(TC)}					
TT 1.1	36.16					[31] ^{ALX}					
Healthcare settings	Metf.						++[35]	++[42] ^{LR}			
TT 1.1 1 '	Mark							[42]ML			
Healthcare ownership	Mett.							++[42]			
Location urbanization	Mett.							++[42]			
Hospital Dets (cat.)	Mett.						++[35]				
Health insurance	Mett.						++[23]	+++[22]			
Co-payment (cat.)	Mett.							+++[22]			
Costs drugs (cat.)	Mett.		++[19]								
Brand/generic ratio	Metf.				++[31]	++[31]					

+++, variable with statistically significant association with the outcome in both univariable and multivariable analyses; ++, variable with statistically significant association with the outcome only in multivariable analysis; +, variable with statistically significant association with the outcome only in univariable analysis; - - -, variable with no statistically significant association with the outcome in both univariable and multivariable analyses; - -, variable with no statistically significant association with the outcome in multivariable analyses -, variable with no statistically significant association with the outcome only in univariable analysis;

Metf., metformin; SU, sulfonylureas; DPP4i, dipeptidyl peptidase-4 inhibitor; W/CVB, drugs without cardiovascular benefits (sulfonylureas, dipeptidyl peptidase-4 inhibitor, thiazolidinediones, α-glucosidase inhibitors, amylin mimetics agents, dopamine receptor agonists, and meglitinides); WCVB, drugs with cardiovascular benefits (Sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists); MT, monotherapy; AHA, other antidiabetic agents can include monotherapy or combination therapy; TZDs, thiazolidinediones; CT, combination therapy; HbA1c, glycated haemoglobin; cont., continuous; cat., categorical;

Databases: 1Data from USA Medicare; 2 Data from Clinformatics; Period: TA Apr 13 to Sept 15; TB Oct 15 to Dec 17; TC Jan 18 to Dec 19; ALX, all except references mentioned in the same space [31]; Statistical analysis used: LRData from logistic regression [42], MLData from multilevel model [42]; (if no indication is provided, a statistically significant association was found in all);

46

Table 6: Strength of association between patient-related factors: sociodemographic, lifestyle and metabolic with the outcomes.

Patient-related factors Sociodemographic				Outco	omes			
01		Metf.	SU	W/CVB	WCVB	MT	AHA	СТ
Age (cont.)	Metf.		+++[36]	++[31]	++[31]		++[30]	
			++[17][19][40]	[31]	[31]		[50]	
			+[16][41]					
	DDD4:	1.[24]	- [10][+1]					
	DPP41	+[24]						
	CI					+[26][27]		
Age (cat.)	Metf.		+++[16]			++[23][34][29]	+++[22]	
			++[18][13][29]				++[37][42]	
	TZDs	++[13]						
	CT	++[13][29]	[13]					
		+[14][15][20]						
Age (cat.) and health insurance	Metf.					++[35]		
Gender	Metf.		+++[16]	++[31]ALX	++[31]ALX	++[23][34][35]	+++[22]	
o childr			++[10]	= -[31]2(TC)	= -[31]1(TA,TB)	[29]	++[42]	
			[36]	[51] ()	[51] ()	[27]	[37][30]	
			[17][12][40][20]				[57][50]	
	770-	[12]	[1/][13][40][29]					
		[15]						
	DPP4i	+[24]						
	СТ	++[13][29]	[13]			+[26]		
						-[27]		
		-[32]						+[32]3
								-[32] ³
Race/Ethnicity	Metf.		+++[16]	++[31]1(TA,TB)	++[31]1(TA,TB)			
			++[19][13]					
	TZDs	[13]						
	СТ	[13]	[13]					
Socioeconomic status	Metf	[10]	++[10]			++[23]	++[42]LR	
socioccononne status	meti.		+[16]			1 [2.5]	[42]ML	
	СТ		1 [10]			[27]	[+2]	
	CI					-[27]	L L L (O)UD	
Doctor or has a doctor in family.							$++[42]^{1.R}$	
	Mett.						[42] ^{ML}	
Geographic region	Metf.		++[19]	++[31]	++[31]			
	СТ					+[26][27]		
Immigrant status	Metf.					+[27]		
Lifestyle and metabolic								
BMI (cont.)	Metf.		++[17][40]					
			+[16]					
	DPP4i	+[24]						
BMI (cat)	Metf	<u>[]</u>	++[18]					
Oberity of everyeight	Motf		[10]	上上[21]	上上[21]			
Smolver (art)	Mett.			[31]	+ + [31]			
Smokel (cat.)	men.			[241ALV	[21]/UR 2/IC			
	Marc		182	[31] ^{ALA}	[31] ^{1(1D),2(1C)}			
Ex-smoker (cat.)	Mett.		+[16]					
			[16]					
Current smoker (cat.)	Metf.		[16]					
			[17]					
Substance abuse (cat.)	Metf.			++[31] ^{2(TA)}	++[31]ALX			
				[31] ^{ALX}	[31]1(TA,TB)			
Liver disease	Metf.		+++[36]					
			++[18]					
	DPP4i	-[24]						
Hyperlipidaemia	Metf.		-[16]	++[31]ALX	++[31]			1
Jr - T			[**]	[31]1(TA),2(TA)	[]			
Dyslinidaemia	Motf		++[20]			++1201		++1201
	M-4f		[[29]			[42]		[1 [29]
HDL (cont.)	Mett.		-[16]					
LDL (cont.)	Mett.		+[16]					
Lipid-lowering meds	Metf.		+++[36]			++[35]		
			[17]					
Statin use	Metf.			++[31]	++[31]			

+++, variable with statistically significant association with the outcome in both univariable and multivariable analyses; ++, variable with statistically significant association with the outcome only in multivariable analysis; - - , variable with statistically significant association with the outcome in both univariable and multivariable analyses; - - , variable with no statistically significant association with the outcome in both univariable and multivariable analyses; - - , variable with no statistically significant association with the outcome in multivariable analyses - , variable with no statistically significant association with the outcome only in univariable analyses; - - , variable with no statistically significant association with the outcome only in univariable analyses; - - , variable with no statistically significant association with the outcome only in univariable analyses; - - , variable with no statistically significant association with the outcome only in univariable analyses; - - , variable analyses; - - , variable with no statistically significant association with the outcome only in univariable analyses; - - , variable with no statistically significant association with the outcome only in univariable analyses;

Metf., metformin; SU, sulfonylureas; W/CVB, drugs without cardiovascular benefits (sulfonylureas, dipeptidyl peptidase-4 inhibitor, thiazolidinediones, α -glucosidase inhibitors, amylin mimetics agents, dopamine receptor agonists, and meglitinides); WCVB, drugs with cardiovascular benefits (Sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists); MT, monotherapy; AHA, other antidiabetic agents can include monotherapy or combination therapy; CT, combination therapy; DPP4i, dipeptidyl peptidase-4 inhibitor; TZDs, thiazolidinediones; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; cont., continuous; cat., categorical;

peptidase-4 inhibitor; TZDs, thiazolidinediones; BMI, body mass index; HDI, high-density lipoprotein; LDL, low-density lipoprotein; cont., continuous; cat., categorical; Databases: ¹Data from USA Medicare; ²Data from Clinformatics; Period: ^{TA} Apr 13 to Sept 15; ^{TB} Oct 15 to Dec 17; ^{TC}] an 18 to Dec 19; ALX, all except references mentioned in the same space [31]; Statistical analysis used.: ^{LR}Data from logistic regression [42], ^{ML}Data from multilevel model [42]; (if no indication is provided, a statistically significant association was found in all);

³Combination therapy between metformin and DPP4i, metformin and SGLT2i, metformin and TZDs (pioglitazone) showed statistical significance, and combination therapy between metformin and sulfonylureas, TZDs (pioglitazone) and DPP4i (alogliptin) did not show statistical significance;

Table 7: Strength of association between patient-related factors: cardiovascular and renal with the outcomes.

Patient-related factors: Cardiovascular	Patient-related factors: Cardiovascular Outcomes								
		Metf.	SU	DPP4i	W/CVB	WCVB	MT	AHA	СТ
Hypertension	Metf.		+++[36] ++[40] +[16]		++[31]	++[31]	[29]		[29]
Coagulopathy	Metf.		[29] +[36]						
			[36]						
Cardiovascular disease	Metf.		++[19] +[16]		++[31]	++[31]		[37]	
IHD	Metf.	-[33]	+[36]				++[35]		
	Mark		[36]				[20]		[20]
IHD/angina	Metf.		[29]				[29]		[29]
HD/hypertension	Meti.		[29]	1 [24]			[29]		[29]
Coronary athorosclarosis of native coronary artery	Bio (T7Da)	±±[20]		+[24]					
Least failure	Motf	1 1 [39]	11112/1				[20]		1 1 201
	Meu.		++[29] +[16]				[29]		1 1 [29]
Valvular disease	Metf.		+++[36]						
Arrhythmia	Metf.		+[36]						
Atrial fibrillation	Metf		++[20]				[20]		[20]
Peripheral vascular disease	Metf.		+[36]				[27]		[27]
i cripiterar vascular disease	inicii.		[36]						
Cerebrovascular disease	Metf.		++[29]				[29]		++[29]
			+[36]						
			[36]						
Micro/macrovascular complications	СТ						+[26]		
Microvascular complications	Metf.				++[31]	++[31] ^{ALX} [31] ^{2(TA)}			
Diabetic retinopathy	Metf.		[36] [18]	+[24]					
Diabetic neuropathy	Metf.		[36] [18]	-[24]					
Cardiovascular meds	Metf.		++[18] ³ [18] ⁴						
Antihypertensive meds	Metf.		[17]				++[35]		
ACE inhibitors or ARBs	Metf.				++[31]	++[31]			
Beta-blockers	Metf.				++[31]1(TB)	[31]			
Calcium channel blockers	Metf.				[31] ^{ALX} ++[31] ¹ (TA)2(TC)	++[31]2(TA,TC)			
	M				[31]^ALX	[31] ^{ALX}			
	Mett.				++[31]	[31] ^{2(TA)}			
Thiazide diuretics	Metf.				++[31]	++[31] ^{ALX} [31] ^{1(TB)}			
Anticoagulants meds	Metf.				++[31] ^{2(TC)} [31] ^{ALX}	++[31] ^{ALX} [31] ^{1(TA)2(TC)}			
Antiplatelet meds	Metf.				++[31]	++[31] ^{ALX} [31] ^{1(TB)2(TB)}			
Renal									
Serum creatinine (cont.)	Metf.		+[16]						
Serum creatinine (cat.)	Metf.		+++[16] ++[13]						[13]
	TZDs	++[13]							
	СТ		++[13]						
Renal disease	Metf.			+[24]				++[37]	
Chronic kidney disease	Metf.		+++[16] ++[19][18]		++[31]	++[31]	[35]		
	СТ						+[27]		
Renal failure	Metf.		+[16]						
	Glip (SU)	++[39]							
Diabetic nephropathy	Metf.		+++[36]	-[24]					
	Glip (SU)	++[39]							

 $64 \\ 65 \\ 66 \\ 68 \\ 70 \\ 72 \\ 73 \\ 74$

+++, variable with statistically significant association with the outcome in both univariable and multivariable analyses; ++, variable with statistically significant association with the outcome only in multivariable analysis; +, variable with statistically significant association with the outcome only in univariable analysis; - - , variable with no statistically significant association with the outcome in both univariable and multivariable analyses; - - , variable with no statistically significant association with the outcome in multivariable analyses - , variable with no statistically significant association with the outcome only in univariable analysis;

Metf., metformin; SU, sulfonylureas; DPP4i, dipeptidase-4 inhibitor; W/CVB, drugs without cardiovascular benefits (sulfonylureas, dipeptidyl peptidase-4 inhibitor; thiazolidinediones, a-glucosidase inhibitors, amylin mimetics agents, dopamine receptor agonists, and meglitinides); WCVB, drugs with cardiovascular benefits (Sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists); MT, monotherapy; AHA, other antidiabetic agents can include monotherapy or combination therapy; CT, combination therapy; Pio, pioglitazone; TZDs, thiazolidinediones; Glip, glipizide; IHD, ischemic heart disease; ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor blockers; cont., continuous; cat., categorical;

Databases: 1Data from USA Medicare; 2Data from Clinformatics; Period: TA Apr 13 to Sept 15; TB Oct 15 to Dec 17; TC Jan 18 to Dec 19; ALX, all except references mentioned in the same space [31] (if no indication is provided, a statistically significant association was found in all); 3current use; 4previous use;



Table 8: Strength of association between patient-related factors: other clinical with the outcomes.

Patient-related factors: Other	tient-related factors: Other Outcomes									
clinical		Metf.	SU	DPP4i	W/CVB	WCVB	MT	AHA	СТ	
Esophageal varices, without bleeding,	Glip	++[39]								
in disease classified elsewhere	(SU)									
Fluid and electrolyte disorder	Metf.		+[36]							
			[36]							
Paracetamol	Pio	++[39]								
	(TZDs)									
COPD	Metf.		+[36]		$++[31]^{1(TA)2(TA)}$	++[31]1(TC)				
21 1			[36]		[31] ^{ALX}	[31] ^{ALX}				
Pulmonary collapse	Pio (TZD)	++[39]								
D	(TZDs)									
Dementia	Metf.		++[18]							
Depression	Metf.		++[29]				[29]		++[29]	
			+[16][36]							
Nouro parchistria modo	СТ		[36]				1 10(1			
A ation what is made	Matf		F1 012 4				+[26]			
Concor	Mett.		[18] ^{3,4}							
Lymphome	Mett.		±120							
Lymphoma	Meu.		⊤[36] [36]							
Hypothyroidism	Metf.		[36]							
Rheumatoid arthritis	Metf.		+[36]							
			[36]							
Immune modulators/suppressants	Metf.		$++[18]^{3}$							
			[18]4							
Oral corticosteroids	Metf.		$++[18]^{3}$							
			[18]4							
Tacrolimus	Glip	++[39]								
	(SU)									
Cefepime	Glip	++[39]								
	(SU)									
Medication use (cont.)	Metf.		[19]				++[23]			
	СТ						+[27]			
Medication use (cat.)	Metf.							+++[22]		
	СТ						+[26]			
Comorbidities (cont.)	Metf.		++[19]							
	СТ						+[27]			
Comorbidities (cat.)	Metf.		++[29]				++[29]	++[30]	++[29]	
Quan Score (cont.)	Metf.		+[16]						<u> </u>	
Rx-Risk comorbidity index (cont.)	CT						+[26]			

81 +++, variable with statistically significant association with the outcome in both univariable and multivariable analyses; ++, variable with statistically 82 significant association with the outcome only in multivariable analysis; +, variable with statistically significant association with the outcome only in univariable 83 analysis; - - -, variable with no statistically significant association with the outcome in both univariable and multivariable analyses; - -, variable with no 84 statistically significant association with the outcome in multivariable analyses -, variable with no statistically significant association with the outcome only in 85 univariable analysis;

86 Metf., metformin; SU, sulfonylureas; DPP4i, dipeptidyl peptidase-4 inhibitor; W/CVB, drugs without cardiovascular benefits (sulfonylureas, dipeptidyl 87 peptidase-4 inhibitor, thiazolidinediones, α -glucosidase inhibitors, amylin mimetics agents, dopamine receptor agonists, and meglitinides); WCVB, drugs 88 with cardiovascular benefits (Sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists); MT, monotherapy; AHA, other 89 antidiabetic agents can include monotherapy or combination therapy; CT, combination therapy; Glip, glipizide; Pio; pioglitazone; TZDs, thiazolidinediones; 90 COPD, chronic obstructive pulmonary disease; cont., continuous; cat., categorical;

91 Databases: 1Data from USA Medicare; 2 Data from Clinformatics; Period: TA Apr 13 to Sept 15; TB Oct 15 to Dec 17; TC Jan 18 to Dec 19; ALX, all except 92 references mentioned in the same space [31] (if no indication is provided, a statistically significant association was found in all); 3current use; 4previous use;

- 93
- 94
- 95
- 96
- 97

Table 9: Strength of association between disease-related factors with the outcomes.

Disease-related factors		Outcomes											
		Metf.	SU	TZDs	DPP4i	W/CVB	WCVB	MT	AHA	СТ			
HbA1c (cont.)	Metf.		++[17][40]		+[24]				++[30]				
			+[16]										
			-[41]										
HbA1c (cat.)	Metf.		+++[16]	[13]						++[13]			
			++[18][13]										
	СТ		++[13]					+[21]					
		+[38]								+[38]			
Fasting glucose (cont.)	Metf.		+[16]										
Random glucose (cont.)	Metf.		+[16]										
Glucose	Pio (TZDs)	++[39]											
Diabetes duration (cont.)	Metf.		++[17][40]										
Time to initiation (cont.)	Metf.		++[17]										
	СТ							+[21]					
Number antidiabetics at	Metf								[37]				
initiation (cat.)													
Diabetes without complications	Pio (TZDs	++[39]											
Hypoglycaemic events (cat.)	Metf.					++[31]ALX	++[31]ALX						
						[31] ^{1(TB)2(TB)}	[31] ^{1(TA,TB)}						
DCSI (cat.)	Metf.								++[42] ^{LR}				
									[42] ^{ML}				

00 +++, variable with statistically significant association with the outcome in both univariable and multivariable analyses; ++, variable with statistically 01 02 significant association with the outcome only in multivariable analysis; +, variable with statistically significant association with the outcome only in univariable analysis; - - - variable with no statistically significant association with the outcome in both univariable and multivariable analyses; - - , variable with no 02 03 04 05 statistically significant association with the outcome in multivariable analyses -, variable with no statistically significant association with the outcome only in univariable analysis;

Metf., metformin; SU, sulfonylureas; TZDs, thiazolidinediones; DPP4i, dipeptidyl peptidase-4 inhibitor; W/CVB, drugs without cardiovascular benefits 06 (sulfonylureas, dipeptidyl peptidase-4 inhibitor, thiazolidinediones, α-glucosidase inhibitors, amylin mimetics agents, dopamine receptor agonists, and 07 meglitinides); WCVB, drugs with cardiovascular benefits (Sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists); MT, 08 monotherapy; AHA, other antidiabetic agents can include monotherapy or combination therapy; CT, combination therapy; Pio; pioglitazone; HbA1c, 09 glycated haemoglobin; DCSI, diabetes complication severity index; cont., continuous; cat., categorical;

10 Databases: 1Data from USA Medicare; 2Data from Clinformatics; Period: TA Apr 13 to Sept 15; TB Oct 15 to Dec 17; TC Jan 18 to Dec 19; ALX, all except 11 references mentioned in the same space [31]; Statistical analysis used: IRData from logistic regression [42], MI Data from multilevel model [42]

12

99

Physician-related factors 313

314 Table 4 shows that physician age presented a statistical association with the prescription profile [22, 42], with older physicians prescribing non-metformin treatments more frequently than metformin. Three studies 315 316 [22, 37, 42] reported a non-association between gender and initial therapy choice. Only Liu et al. [42] found that male physicians had a higher chance of prescribing non-metformin than female physicians in logistic 317 318 regression. Physician speciality was the most assessed variable in this category, with six studies [22, 25, 28, 30, 31, 42] showing a statistically significant association. Campbell et al. [30] stated that specialists were more 319 likely to prescribe metformin in combination or other drug therapies instead of metformin alone compared 320 to general practitioners (GPs). Pinto et al. [25] also reported that GPs had a lower prevalence of prescribed 321 combined therapy than other specialists (4.2% vs 33.3%, p-value <0.001). However, no significant 322 differences were found in the prescription rates of metformin alone or in combination between GPs and 323 other specialists. Another study [42] presented that GPs had a higher chance of prescribing non-metformin 324 than metformin compared to endocrinologists. In contrast, Shin et al.[31] observed that individuals visiting 325 endocrinologists had a lower chance of initiating metformin than other drugs independently of their 326 327 cardiovascular benefits; the opposite was found when visiting internists. Finally, the two additional variables, years of experience and the medical evidence questionnaire, assessed by Wang et al. [37] presented a non-328 329 statistically significant association.

Healthcare system-related factors 330

Eleven studies [13, 16, 17, 19, 22, 23, 29, 31, 35, 36, 42] demonstrated a statistically significant association 331 between more recent time periods and the prescription profile. However, in two studies, this depended on 332 333 the analysed database [31] or medicine and the respective comparison [13] to report statistical significance. Studies reported that the most recent periods were positively associated with metformin initiation [19, 31], 334 and also when compared with sulfonylureas [16, 17, 29, 36], other monotherapies [23, 35], other antidiabetic 335 agents (eventually in monotherapy or combination therapy) [22, 42] or combination therapy [29]. 336 337 Additionally, Wang et al. [37] studied how primary care physicians responded to a change in the Canadian Diabetes Association Guidelines, which significantly increased metformin initiation as a first line, except 338 339 when compared to sulfonylureas.

One cross-sectional study [31] reported that individuals with three or more HbA1c tests within 365 days before the index date had higher odds of initiating any other medicine than metformin, irrespective of their cardiovascular benefits. Additionally, variables such as the number of office visits [24, 36], hospitalisations [19, 36], emergency visits [36], and the length of stay [22] were statistically significantly associated with lower odds of metformin prescriptions. However, Abdelmoneim *et al.* [36] and Shin *et al.* [31] reported no statistically significant association with some of these variables (see Table 5).

346 Two studies [22, 23] reported an association between the health insurance and the initial therapy choice. 347 Regarding the co-payment and cost of drugs, one study [22] indicated that individuals with co-payment waiver had a lower chance of starting metformin than sulfonylureas, the same that Li [19] found for 348 349 individuals in the top 10% of prescription drug expenses under Medicare Part D. Medicare is a health 350 program for individuals aged 65 and over and younger individuals with disabilities, with Medicare Part D 351 being an optional plan that covers drug costs [44]. Shin et al. [31] stated that individuals with more brandname experience also had a lower chance of starting metformin than drugs independently of their 352 353 cardiovascular benefits.

354 Patient-related factors: Sociodemographic

355 Twenty-two studies [13–20, 22–24, 26, 27, 29–31, 34, 36, 37, 40–42] evaluated the association between 356 age and initial therapy choice. Metformin prescription was associated with younger individuals compared to 357 sulfonylureas [13, 16-19, 29, 36, 40, 41], other antidiabetic agents (including monotherapy (MT) and eventually MT and combination therapy (AHA)) [22, 29, 30, 34, 37, 42], thiazolidinediones [13], DPP4i [24], 358 359 and drugs without cardiovascular benefits [31]. Even when the interaction between age and type of insurance 360 was studied [35], metformin prescription decreased with advancing age compared to other monotherapies. 361 On the other hand, when metformin is compared with drugs with cardiovascular benefits, the chance of prescribing increases with age [31]. Two studies [13, 29] found a significant but inverse association between 362 363 age and combination therapy. The other two studies [26, 27] indicated that younger people were more 364 prevalent in combination therapy than monotherapy. Moreover, one study [13] found no association 365 between age and combination therapy compared to sulfonylureas.

Nineteen studies tested the association between gender and prescription profile [13, 16, 17, 19, 22–24,
26, 27, 29–32, 34–37, 40, 42]. Nine studies [16, 19, 22–24, 26, 34, 35, 42] showed a statistically significant

368 association and six none[17, 27, 30, 32, 37, 40]. In the remaining four studies [13, 29, 31, 32] several analysis 369 were conducted within each study. This led to the report of statistically significant associations depending 370 on the prescribing profile evaluated (i.e., the same study analysed different prescribing profiles with gender) 371 or the database analysed (i.e., the same study analysed two different databases). The statistical associations 372 found that females were more likely to initiate metformin than men compared to sulfonylureas [16, 19], other monotherapies [34, 35], other antidiabetic agents [42] or DPP4i [24]. On the other hand, Winkelmayer 373 374 et al. [22] identified a significant association, though its direction varied between univariate and multivariate 375 analyses, and Desai et al. [23] noted that men had a higher chance of starting metformin than other 376 monotherapies.

Regarding race/ethnicity, black individuals showed a lower chance of starting metformin than sulfonylureas compared to white individuals [13, 16, 19]. White individuals also showed more chance of starting drugs with cardiovascular benefits than metformin compared to non-white [31]. However, there was no statistically significant association between race/ethnicity and combination therapy compared to metformin or sulfonylureas [13].

Individuals with lower socioeconomic status were associated with more frequent non-metformin prescriptions [23, 42] or sulfonylurea prescriptions [16, 19], compared to metformin. Conversely, Liu *et al.* [42] also found the same for a higher socioeconomic status category, and statistical significance was lost in the multilevel linear model.

386 **Patient-related factors: Lifestyle and metabolic**

387 Nine studies [16–18, 24, 29, 31, 35, 36, 40] evaluated at least one lifestyle or metabolic variable (Table 388 6). A higher body mass index (BMI) was significantly associated with an increased chance of starting 389 metformin compared to sulfonylureas [16–18, 40], DPP4i [24], or drugs without cardiovascular benefits[31]. 390 However, when compared to drugs with cardiovascular benefits, the chance of prescribing metformin 391 decreased with a higher BMI [31]. Liver disease was associated with a decreased chance of starting metformin compared to sulfonylureas [18, 36]. However, no statistical significance was found when 392 393 compared to DPP4i. Individuals with dyslipidaemia showed higher odds of initiating combination therapy than metformin [29]. For other variables in this group, either no statistical significance was found, or the 394 395 direction of associations was inconclusive.

Patient-related factors: Cardiovascular 396

397 The impact of twenty-seven cardiovascular variables (the most representative group of variables) was assessed in fourteen studies [16-19, 24, 26, 29, 31, 33, 35-37, 39, 40]. Hypertension was evaluated with 398 399 initial therapy choice in five studies [16, 29, 31, 36, 40]. Three studies [16, 36, 40] showed statistical significance, but with conflicting results. Abdelmoneim et al. [36] found that hypertension increased the odds 400 401 of starting metformin compared to sulfonylureas, while Fujihara et al. [40] reported the opposite. Shin et al. 402 [31] also linked hypertension to a decreased chance of starting metformin compared to drugs with or without 403 cardiovascular benefits. However, Shin et al. [31] found that the use of angiotensin-converting enzyme 404 inhibitors and angiotensin receptor blockers (antihypertensive drugs) increased the odds of initiating 405 metformin. No significant association was found between hypertension and combination therapy compared 406 to metformin [29].

407 Two studies [16, 19] reported that cardiovascular disease was negatively associated with metformin initiation compared to sulfonylureas. Similarly, Shin et al. [31] found the same when comparing metformin 408 to drugs with or without cardiovascular benefits. No statistically significant association was found by Wang 409 410 et al. [37].

411 Three studies [16, 29, 36] reported that heart failure was negatively associated with metformin compared 412 to sulfonylureas. Additionally, Wood et al. [29] reported that individuals with heart failure had higher odds of initiating combination therapy rather than metformin. Similarly, cerebrovascular disease decreased the 413 414 odds of initiating metformin compared to sulfonylureas or combination therapy, although no significant 415 association was found when comparing metformin to non-metformin therapies for either heart failure or 416 cerebrovascular disease [29]. The valvular disease kept the tendency reported, and it was associated with a 417 decreased chance of initiating metformin compared to sulfonylureas [36].

418

Patient-related factors: Renal

419 Eleven studies [13, 16, 18, 19, 24, 27, 31, 35–37, 39] evaluated renal-related variables. It is unanimously reported that renal problems, such as elevated serum creatinine, renal disease, chronic renal disease (CKD), 420 renal failure and diabetes-related nephropathy decreased the chance of metformin initiation [13, 16, 18, 19, 421 24, 31, 35-37, 39]. For example, Raebel et al.[16] showed that individuals with serum creatine range of 1.4 422

to $\leq 2 \text{ mg/dl}$ compared to individuals with $\leq 1.4 \text{mg/dl}$ (reference) had a relative risk of 2.21 (95% CI, 2.05-2.39) of starting sulfonylureas compared to metformin and Wang *et al.* [37] also showed that individuals with renal disease had lower odds (OR 0.14; 95% CI, 0.05-0.40) of starting metformin than other antidiabetic agents.

Regarding combination therapy, Brouwer *et al.* [13] reported that high serum creatinine decreased the chance of beginning combination therapy compared to sulfonylureas, and another study [27] stated a lower prescription of combination therapy compared to monotherapies such as sulfonylureas or DPP4i among individuals with CKD [27].

431 **Patient-related factors: Other clinical**

432 Twenty-one other clinical variables were assessed with the prescription profile in twelve studies [16, 18, 19, 22, 23, 26, 27, 29–31, 36, 39]. Of these, 81% (17) of the variables were assessed by one study. Dementia 433 was negatively associated with metformin initiation compared to sulfonylureas [18]. Wood et al. [29] reported 434 that depression was positively associated with metformin initiation compared to sulfonylureas, which 435 aligned with Raebel et al. [16] findings. However, these associations differed in direction from the univariable 436 437 analysis results reported by Abdelmoneim et al. [36]. Wood et al. [29] also reported that depression was positively associated with metformin initiation compared with combination therapy, and statistical 438 439 significance was not found comparing non-metformin monotherapies with metformin. Juste et al. [26] reported that the prevalence of neuro-psychiatric medication was higher among monotherapy initiators than 440 441 among combination therapy initiators.

Regarding medication use, Desai *et al.* [23] reported that the chances of starting metformin than other monotherapies decreased for each additional prescription. However, Li [19] found no statistical association, and Winkelmayer *et al.* [22] observed that the odds of initiating metformin increased with a higher number of therapeutic class prescriptions compared to other antidiabetic agents. However, this pattern shifted in the univariable analysis, where individuals taking \geq 9 medications had reduced odds of initiating metformin compared to those taking none. Two studies[26, 27] stated that the prevalence another type of medication was higher among monotherapy initiators than among combination therapy initiators.

Wood *et al.* [29] presented that individuals with one to three comorbidities had a lower chance of starting
sulfonylureas than metformin compared to those with no comorbidities. No statistically significant

451 association was found when comparing four or more comorbidities to zero. Additionally, individuals with 452 one to six comorbidities had lower odds of initiating non-metformin monotherapy compared to metformin, 453 though this was not statistically significant when comparing seven or more comorbidities to zero. 454 Nevertheless, compared to zero, one or more comorbidities reduced the odds of initiating combination 455 therapy rather than metformin. Campbell et al. [30] also reported that individuals with one or more comorbidities were less likely to start metformin in combination therapy or other drug therapies, instead of 456 457 metformin alone compared to those with no comorbidities. Additionally, Juste et al. [26] noted that 458 individuals who initiated combination therapy had a lower comorbidity score compared to individuals who 459 initiated monotherapy.

460 **Disease-related factors**

Data was extracted from fourteen studies [13, 16–18, 21, 24, 30, 31, 37–42] with ten variables collected. 461 HbA1c was the most studied variable, being addressed in ten studies [13, 16–18, 21, 24, 30, 38, 40, 41]. Five 462 studies [13, 16-18, 40] stated that higher HbA1c levels were statistically associated with the initial 463 sulfonylureas therapy instead of metformin, but one study did not find statistical significance [41]. Campbell 464 465 et al. [30] also indicated that individuals with a higher HbA1c level were more likely to start non-metformin and combination therapy than metformin alone. On the other hand, Morita et al. [24] reported the opposite 466 467 when comparing metformin to DPP4i, and no statistically significant association was noted when comparing 468 metformin to thiazolidinediones [13]. Combination therapy was statistically associated with higher levels of 469 HbA1c compared to metformin, sulfonylureas [13] or monotherapy [21].

470 Raebel *et al.* [16] also assessed fasting and random glucose levels and reported that both levels were 471 higher among those who initiated sulfonylureas than those who initiated metformin in univariable analysis. 472 Vashisht *et al.* [39] identified glucose and diabetes without complications as variables statistically associated 473 with pioglitazone (TZD) choice instead of metformin. However, the researchers did not specify how glucose 474 was measured, nor did they clarify whether the association with pioglitazone was positive or negative.

Shorter diabetes duration [17, 40] and earlier treatment initiation [17] were statistically associated with metformin initiation compared to sulfonylureas. Ouchi *et al.* [21] also found that combination therapy (89.62 days, SD 279.1) was prescribed significantly earlier (p<0.001) than monotherapy (190.7 days, SD 366.2).

Quality assessment 479

480 The quality assessment results for observational cohort studies are presented in Table 10. None of the 481 studies ensured the similarity between compared groups (exposed vs. unexposed). It was also impossible to 482 ensure exposures measured similarly between groups and their validity and reliability as all studies relied on 483 secondary data without detailing the method of exposure measurement. None of the studies identified 484 potential confounders or strategies to address them. Five studies [13, 16, 17, 19, 21] raised concerns about 485 outcome validity and reliability, as the data sources might have reflected treatment adherence (e.g., pharmacy 486 dispensing records) rather than prescriptions. Follow-up loss was either ignored [17] or avoided through 487 inclusion/exclusion criteria [13-16, 18-21] without strategies being expected to address it. Although five 488 studies [13, 16-19] used multivariable analysis (appropriate statistical analysis considered), none reported statistical model assumptions, and one study [21] did not report the applied statistical analysis. 489

- 490
- 491

Table 10: Quality assessment and risk of bias of cohort studies included.

		Topics assessed											
Retrospective	D1	D2	D3	D4	D5	D6	D7	D8	D9	D10	D11		
cohort studies													
Brouwer et al.[13]	Unclear	Unclear	Unclear	No	No	Unclear	Unclear	Yes	Unclear	N/A	Unclear		
Zhang et al. [14]	Unclear	Unclear	Unclear	No	No	Yes	Yes	Yes	Unclear	N/A	No		
Sinclair et al. [15]	Unclear	Unclear	Unclear	No	No	Yes	Yes	Yes	Unclear	N/A	No		
Raebel et al. [16]	Unclear	Unclear	Unclear	No	No	Yes	Unclear	Yes	Unclear	N/A	Unclear		
Geier et al. [17]	Unclear	Unclear	Unclear	No	No	Yes	Unclear	Yes	Unclear	N/A	Unclear		
Wright [18]	Unclear	Unclear	Unclear	No	No	Yes	Yes	Yes	Unclear	N/A	Unclear		
Li [19]	Unclear	Unclear	Unclear	No	No	Yes	Unclear	Yes	Unclear	N/A	Unclear		
Carrillo Balam	Unclear	Unclear	Unclear	No	No	Yes	Yes	Yes	Unclear	N/A	No		
[20]													
Ouchi et al. [21]	Unclear	Unclear	Unclear	No	No	Unclear	Unclear	Yes	Unclear	N/A	Unclear		

492 493 494 495 D1. Were the two groups similar and recruited from the same population? D2. Were the exposures measured similarly to assign people to both exposed and unposed groups? D3. Was the exposure measured in a valid and reliable way? D4. Were confounding factors identified? D5. Were strategies to deal with confounding factors stated? D6. Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? D7. Were the outcomes measured in a valid and reliable way? D8. Was the follow up time reported and sufficient to be long enough 496 for outcomes to occur? D9. Was follow up complete, and if not, were the reasons to loss to follow up described and explored? D10. Were strategies 497 to address incomplete follow up utilized? D11. Was appropriate statistical analysis used? N/A, not applicable;

498

499 Table 11 presents the results of quality assessment for observational cross-sectional studies. Eight studies [24, 28, 30, 32, 38–41] did not provide clear inclusion criteria, and eight studies [23, 25, 32–34, 39–41] lacked 500 501 information to infer the health status of the sample. It was also impossible to ensure exposures measured validity and reliability. However, four studies [23, 25, 32, 34] reported exposures without a gold standard 502 503 measurement (e.g., age, sex, type of insurance), suggesting no risk of bias. Only two studies [30, 45] identified

504 potential confounders, but their statistical models also examined associations with the outcome, raising 505 doubts about their exclusive use for control. Therefore, only two other studies [28, 33] addressed confounder factors by matching or stratification. Twelve studies [22, 23, 26, 27, 29-31, 34, 36-38, 42] relied 506 507 on pharmacy dispensing data or lacked clarity on data sources, undermining outcome validity and reliability. 508 None used appropriate statistical analyses due to missing multivariable analysis [24–28, 32, 33, 38, 41], 509 unreported statistical model assumptions [22, 23, 29-31, 34-37, 40, 42], or omission of p-value results [39]. 510 Therefore, the quality assessment underscores multiple issues across the studies, pointing to a high risk of 511 bias.

- 512

513

Table 11: Quality assessment and risk of bias of cross-sectional studies included.

		Topics assessed						
Cross-sectional studies	D1	D2	D3	D4	D5	D6	D7	D8
Winkelmayer et al.[22]	Yes	Yes	Unclear	Yes	No	No	Unclear	Unclear
Desai et al.[23]	Yes	No	N/A	Yes	No	No	Unclear	Unclear
Grimes et al. [34]	Yes	No	N/A	Yes	No	No	Unclear	Unclear
Abdelmoneim et al.[36]	Yes	Yes	Unclear	Yes	No	No	Unclear	Unclear
Wang et al. (2013)[37]	Yes	Yes	Unclear	Yes	Yes	Unclear	Unclear	Unclear
Mitchell et al.[38]	No	Yes	Unclear	Unclear	No	No	Unclear	No
Vashisht et al.[39]	No	No	Unclear	Yes	No	No	Yes	Unclear
Fujihara et al. [40]	No	No	Unclear	Unclear	No	No	Yes	Unclear
Tanabe et al. [41]	No	No	Unclear	Unclear	No	No	Yes	No
Liu et al. [42]	Yes	Yes	Unclear	Yes	No	No	Unclear	Unclear
Morita et al. [24]	No	Yes	Unclear	Yes	No	No	Yes	No
Pinto et al. [25]	Yes	No	N/A	Yes	No	No	Yes	No
Juste et al.[26]	Yes	Yes	Unclear	Yes	No	No	Unclear	No
Moreno-Juste et al. [27]	Yes	Yes	Unclear	Yes	No	No	Unclear	No
Yabe et al. [28]	No	Yes	Unclear	Unclear	No	Yes	Yes	No
Wood et al. [29]	Yes	Yes	Unclear	Yes	No	No	Unclear	Unclear
Campbell et al.[30]	No	Yes	Unclear	Yes	Yes	Unclear	Unclear	Unclear
Shin et al. (2021)[31]	Yes	Yes	Unclear	Yes	No	No	Unclear	Unclear
Bonora et al.[32]	No	No	N/A	No	No	No	Yes	No
Barth et al.[33]	Yes	No	Unclear	Yes	No	Yes	Yes	No
Bouchi et al.[35]	Yes	Yes	Unclear	Yes	Unclear	Unclear	Yes	Unclear

D1. Were the criteria for inclusion in the sample clearly defined? D2. Were the study subjects and the setting described in detail? D3. Was the exposure measured in a valid and reliable way? D4. Were objective, standard criteria used for measurement of the condition? D5. Were confounding

514 515 516 517 factors identified? D6. Were strategies to deal with confounding factors stated? D7. Were the outcomes measured in a valid and reliable way? D8. Was appropriate statistical analysis used? N/A, not applicable;

518

519

521 **Discussion**

This systematic review identified 30 studies exploring factors influencing first-line treatment decisions in T2DM, focusing on metformin and combination therapy. Although clinical decisionmaking can be inherently complex, the identification of key factors serves two main purposes: first, it enables the alignment of clinical practice with evidence-based guidelines by addressing gaps in knowledge and practice patterns; second, it aids in tailoring treatment decisions to individual characteristics, thereby enhancing the quality of care and improving health outcomes.

528 The prevalence of the two initial therapies analysed varied widely across studies, with the greatest 529 variation observed in metformin initiation. For instance, Morita et al. [24] reported that 7.1% of their 530 sample started metformin monotherapy, while Campbell et al. [30] found that 89% of participants initiated metformin monotherapy. This discrepancy may be attributed to differences in national 531 532 clinical guidelines: Canadian guidelines recommend metformin as the first-line treatment unless 533 contraindicated [46], while Japanese guidelines do not specify a preferred drug for initiation [47]. This 534 highlights how variations in regional clinical recommendations can significantly impact treatment 535 patterns and decision-making processes.

536 One hundred and five variables were evaluated as potential predictive factors influencing initial 537 therapy decisions, with only 9.5% (10) showing no association with initial therapy choice. Among 538 these, 25 variables were assessed with combination therapy, with 18 (72%) evaluated in just one study. 539 Notably, only 11 of the 105 variables were assessed in five or more studies, indicating limited 540 replication and, consequently, reduced robustness for most findings.

Age and gender were the most frequently assessed variables, reflecting the accessibility of demographic data. On the other hand, physician-related factors were the group with the least variables evaluated, perhaps due to challenges in extracting this information from secondary data sources. In contrast, the subgroup of cardiovascular factors included the highest number of assessed variables, which may reflect researchers' interest in studying these factors and the emphasis of guidelines on cardiovascular diseases in individuals with T2DM [48, 49]. Furthermore, among the twenty-one variables categorized as other clinical factors, doubts arise about their clinical basis for

548 assessing their association with the initial therapy choice, potentially indicating that their availability

549 is the primary reason for their assessment.

550 Interestingly, while physician age was associated with initial therapy choice, years of experience 551 were not, yielding contradictory results since age is typically linked to years of experience. Moreover, 552 a survey study [50] found that years of experience influenced the factors considered when selecting 553 first-line treatment, and a chart review study [51] revealed that more experienced physicians were less 554 likely to follow guidelines. These findings highlight the complexity of physician-related factors and 555 their interplay with clinical decision-making. Additionally, regarding associations found with 556 physician specialities, it is important to consider that access to these specialities is strongly influenced 557 by the patient's health status and the severity of the disease [52]. Healthcare utilization is also 558 significantly affected by the patient's socioeconomic status[53], and both socioeconomic status and 559 health insurance were associated with initial therapy choice.

Patient-related factors, particularly age, also play a significant role in influencing therapy decisions, with metformin consistently linked to a younger age. A survey study [54] also reported that reasons cited by physicians to avoid initial dual therapy were often associated with patient age. Additionally, metformin initiation was negatively associated with several cardiovascular conditions and healthcare utilization, indicating a tendency to avoid metformin in individuals with poorer health status. This trend is surprising given its well-established safety profile [55] and its benefits for various conditions [56].

567 Concerns about these findings are heightened when comparing metformin to sulfonylureas, which 568 are associated with an increased risk of hypoglycaemia [57]. Guidelines recommend a conservative 569 approach to sulfonylureas, particularly in older individuals [4, 7, 58], and scientific literature highlights 570 their potential harm in those at high risk for cardiovascular disease [59]. The preference for 571 sulfonylureas over metformin at high HbA1c levels is not also supported by guideline 572 recommendations [4] or scientific literature [60, 61].

573 On the other hand, renal-related factors present a valid reason for avoiding metformin, as it should 574 not be used in individuals with an estimated glomerular filtration rate <30 ml/min per 1.73 m² [62]. 575 This may explain why studies report that physicians are cautious about prescribing it to individuals

with renal problems. Similarly, for BMI, the findings also align with guideline recommendations [4,7].

The positive association between high HbA1c levels and combination therapy is consistent with recommendations, particularly the consensus report from the ADA and EASD [4], which advocates for considering initial combination therapy in individuals with elevated HbA1c at diagnosis. Additionally, the tendency to avoid combination therapy in individuals with a high number of comorbidities aligns with Ismail-Beigi *et al.* [63], who highlighted the importance of less intensive treatment for those with multiple or severe comorbidities.

584 While these findings are noteworthy, it is important to recognize the significant methodological 585 limitations and weaknesses that affect their validity and reliability. There is a lack of clear definitions 586 for the medications included in combination therapy and those used as the reference category for 587 comparison. Many studies simply refer to "combination therapy" and "other antidiabetic drugs," 588 leading to ambiguity. Moreover, different reference categories were used for comparison with 589 metformin or combination therapy. For instance, one study compared metformin alone or in 590 combination with other antidiabetic medications that did not include metformin [37], while another 591 compared metformin alone to other antihyperglycemic agents, including metformin used in 592 combination therapy [30]. Adding to it is the inconsistent definition of independent variables and the 593 variation in their collection times across studies. These inconsistencies not only hinder comparisons 594 between studies but also undermine the external validity of the findings, limiting their generalizability. 595 The lack of efforts to ensure the similarity of groups and to identify and address potential 596 confounder factors brought possible bias. For example, Zhang et al. [14] divided their sample into 597 individuals <65 years and ≥ 65 years and reported twenty-five statistically significant differences 598 between the two groups in twenty-nine variables analysed. This aligns with the scientific literature 599 that has shown that the prevalence of cardiovascular disease increases with age [64], CKD is more 600 common among older individuals [65], and multimorbidity is also more prevalent in older adults, 601 strongly associated with increased healthcare utilization and costs [66, 67]. This information, along 602 with the quality assessment results, raises concerns about the internal validity of the studies and 603 suggests a high risk of bias in the findings.

Despite these internal and external validity concerns, some observed clinical practices deviate from established guidelines and scientific literature. This misalignment highlights an urgent need to bridge the gap between clinical practice and evidence-based recommendations. Furthermore, more robust studies are essential, particularly those that emphasize external validation and minimize the risk of bias. These studies should facilitate direct comparisons across research, providing a more reliable basis for developing evidence-based recommendations grounded in high-quality data.

610

611

Strengths and limitations

As far as we know, this is the first systematic review to map all factors driving physicians to choose metformin or combination therapy as first-line treatment. This review offers an exhaustive overview of the scientific literature, as no time or language restrictions were imposed, and grey literature was also included. Furthermore, compared to Mahmoud *et al.* [68], who conducted a meta-analysis of factors influencing antidiabetic drug prescribing for T2DM, including initiation therapy, this review expands the scope by incorporating nineteen additional studies.

All studies assessing the outcomes of interest were included, regardless of the reference group used for comparison. This approach allowed for a broad range of comparisons but also introduced heterogeneity into the analysis. Moreover, the weak evidence in the main findings due to the low quality of the studies, which integrated this systematic review, should not be overlooked.

622

623 Conclusion

This systematic review identified several factors associated with metformin and combination therapy as first-line therapies in T2DM, revealing clinical practices not aligned with evidence-based medicine. However, few studies have focused on combination therapy, assessing physician-related factors, and even fewer have compared metformin with newer drugs, such as SGLT2i. Additionally, the studies included in the review exhibited low certainty evidence. Therefore, a robust methodology is needed to bring scientific evidence. As a result, further research is required to address these

630 weaknesses and potential biases, provide stronger evidence, and ultimately support the findings

631 reported in this review.

632

633 Acknowledgements

634 We would like to thank Mandy Ryan and Michael Abbott, who supervised MH at the Health

635 Economics Research Unit at the University of Aberdeen, for their help in developing this study,

- 636 which is integrated into her master's thesis.
- 637
 638
 639
 640
 641
 642
 643
 644
 645
 646
 647
 648
 649
- 650
- 651
- 652
- 653
- 055
- 654

655 **References:**

- Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of type 2 diabetes mellitus. Int J
 Mol Sci 2020; 21: 1–34.
- Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes
 prevalence estimates for 2021 and projections for 2045. *Diabetes Res Clin Pract* 2022; 183: 109119.
- Saeedi P, Salpea P, Karuranga S, et al. Mortality attributable to diabetes in 20-79 years old adults, 2019
 estimates: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2020; 162: 108086.
- [4] Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A
 Consensus Report by the American Diabetes Association (ADA) and the European Association for
 the Study of Diabetes (EASD). *Diabetes Care* 2022; 45: 2753–2786.
- Engler C, Leo M, Pfeifer B, et al. Long-term trends in the prescription of antidiabetic drugs: real-world
 evidence from the Diabetes Registry Tyrol 2012-2018. *BMJ open diabetes Res care*; 8. Epub ahead of print
 September 2020. DOI: 10.1136/bmjdrc-2020-001279.
- 669 [6] American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to
 670 Glycemic Treatment: Standards of Medical Care in Diabetes-2022. *Diabetes Care* 2022; 45: S125–S143.
- [7] (NICE) LNI for H and CE. Type 2 diabetes in adults: management. *NICE Guideline, No. 28.* DOI:
 32023018.
- 673 [8] Corallo AN, Croxford R, Goodman DC, et al. A systematic review of medical practice variation in
 674 OECD countries. *Health Policy* 2014; 114: 5–14.
- 675 [9] Birkmeyer JD, Reames BN, McCulloch P, et al. Understanding of regional variation in the use of
 676 surgery. *Lancet (London, England)* 2013; 382: 1121–9.
- 677 [10] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for
 678 reporting systematic reviews. *BMJ* 2021; 372: n71.
- 679 [11] Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews.
 680 Syst Rev 2016; 5: 210.
- 681 [12] Aromataris E, Munn Z (eds). *JBI Manual for Evidence Synthesis*. JBI. Epub ahead of print 2020. DOI:
 682 10.46658/JBIMES-20-01.
- [13] Brouwer ES, West SL, Kluckman M, et al. Initial and subsequent therapy for newly diagnosed type 2
 diabetes patients treated in primary care using data from a vendor-based electronic health record. *Pharmacoepidemiol Drug Saf* 2012; 21: 920–928.
- [14] Zhang Q, Rajagopalan S, Marrett E, et al. Time to treatment initiation with oral antihyperglycaemic
 therapy in US patients with newly diagnosed type 2 diabetes. *Diabetes, Obes Metab* 2012; 14: 149–154.
- 688 [15] Sinclair AJ, Alexander CM, Davies MJ, et al. Factors associated with initiation of antihyperglycaemic
 689 medication in UK patients with newly diagnosed type 2 diabetes. *BMC Endocr Disord* 2012; 12: 1–7.
- [16] Raebel MA, Xu S, Goodrich GK, et al. Initial Antihyperglycemic Drug Therapy Among 241 327 Adults
 With Newly Identified Diabetes From 2005 Through 2010: A Surveillance, Prevention, and
 Management of Diabetes Mellitus (SUPREME-DM) Study. *Ann Pharmacother* 2013; 47: 1280–1291.
- 693 [17] Geier AS, Wellmann I, Wellmann J, et al. Patterns and determinants of new first-line
 694 antihyperglycaemic drug use in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2014; 106:
 695 73–80.

medRxiv preprint doi: https://doi.org/10.1101/2025.01.22.25320805; this version posted January 25, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

		/
It is made available	under a CC-B	Y 4.0 International license .

696	[18]	Wright AK Examining Drug Utilisation Patterns and Optimal Treatment Pathways of Antidiabetic Medications
697	[10]	The University of Manchester,
698		https://pure.manchester.ac.uk/ws/portalfiles/portal/54566935/FULL TEXT.PDF (2014).
699	[19]	Li Y. Factors Associated with Initiation of Glucose-lowering Agents among Medicare Beneficiaries with Newly
700	C J	Diagnosed Type 2 Diabetes, 2007 – 2017. University of Pittsburgh. Epub ahead of print 2019. DOI:
701		10.1159/000382900.
702	[20]	Carrillo Balam GG. Glucose-lowering medication initiation in people with newly diagnosed type 2 diabetes in Scotland:
703		A mixed-methods study. The University of Edinburgh. http://dx.doi.org/10.7488/era/869 (2020).
704	[21]	Ouchi D. Giner-Soriano M. Vilaplana-Carnerero C. et al. Longitudinal treatment patterns in patients
705		recently diagnosed with type 2 diabetes mellitus in Catalonia. <i>Diabetes Res Clin Pract</i> 2023: 202: 110777.
706	[22]	Winkelmaver WC, Stedman MR, Pogantsch M, et al. Guideline-conformity of initiation with oral
707	[]	hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
708		Pharmacoepidemiol Drug Saf 2011: 20: 57–65.
709	[23]	Desai NR. Shrank WH. Fischer MA. et al. Patterns of medication initiation in newly diagnosed diabetes
710	[]	mellitus: Quality and cost implications. Am I Med 2012; 125: 302.e1-302.e7.
711	[24]	Morita Y, Murayama H, Odawara M, et al. Treatment patterns of drug-naive patients with type 2
712		diabetes mellitus: A retrospective cohort study using a Japanese hospital database. <i>Diabetol Metab Syndr</i>
713		2019; 11: 1–10.
714	[25]	Pinto D, Rodrigues AP, Nunes B. Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese
715	C J	Sentinel Practice Network. Acta Med Port 2019; 32: 375–380.
716	[26]	Juste AM, Menditto E, Orlando V, et al. Treatment patterns of diabetes in Italy: A population-based
717	C J	study. Front Pharmacol 2019; 10: 1–11.
718	[27]	Moreno-Juste A, Poblador-Plou B, Aza-Pascual-Salcedo M, et al. Initial therapy, regimen change, and
719		persistence in a spanish cohort of newly treated type 2 diabetes patients: A retrospective, observational
720		study using real-world data. Int J Environ Res Public Health; 17. Epub ahead of print 2020. DOI:
721		10.3390/ijerph17103742.
722	[28]	Yabe D, Higashiyama H, Kadowaki T, et al. Real-world Observational Study on Patient Outcomes in
723		Diabetes (RESPOND): Study design and baseline characteristics of patients with type 2 diabetes newly
724		initiating oral antidiabetic drug monotherapy in Japan. BMJ Open Diabetes Res Care 2020; 8: 1–11.
725	[29]	Wood SJ, Magliano DJ, Bell JS, et al. Pharmacological treatment initiation for type 2 diabetes in
726		Australia: are the guidelines being followed? Diabet Med 2020; 37: 1367-1373.
727	[30]	Campbell DJT, Campbell DB, Ogundeji Y, et al. First-line pharmacotherapy for incident type 2
728		diabetes: Prescription patterns, adherence and associated costs. Diabet Med; 38. Epub ahead of print
729		2021. DOI: 10.1111/dme.14622.
730	[31]	Shin HJ, Schneeweiss S, Glynn RJ, et al. Trends in First-Line Glucose-Lowering Drug Use in Adults
731		With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care 2021;
732		44: 1774–1782.
733	[32]	Bonora E, Cataudella S, Marchesini G, et al. Initial treatment of diabetes in Italy. A nationwide
734		population-based study from of the ARNO Diabetes Observatory. Nutr Metab Cardiovasc Dis 2021; 31:
735		2661–2668.
736	[33]	Barth SD, Kostev K, Krensel M, et al. Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-

medRxiv preprint doi: https://doi.org/10.1101/2025.01.22.25320805; this version posted January 25, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

			,	
It is made available	under a	СС-ВУ	Y 4.0 International license .	

737		alucase Contransporter 2 Inhibitor Drescriptions in Cormany Reflect Recommendations for Type 2
738		Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report? Even Clin Endocrinol
739		Diabetes Epub abead of print 2022 DOI: 10.1055/a-1927-4454
740	[3/]	Grimes RT Bennett K Tilson L et al. Initial therapy persistence and regimen change in a cohort of
741	[דכ]	newly treated type 2 diabetes patients. Br L Clin Pharmaral 2014: 70: 1000–1009
742	[35]	Rouchi P. Sugiyama T. Coto A. et al. Retrospective nationwide study on the trends in first line
743	[55]	aptidiabatic medication for patients with type 2 diabates in Japan 1 Diabates Investig 2022; 13: 280, 201
744	[36]	Abdelmoneim AS, Eurich DT, Camble IM, et al. Use patterns of antidiabetic regimens by patients with
745	[50]	type2 diabetes Can I Diabate 2013: 37: 394 400
746	[37]	Wang T.V. Equale T. Tamblyn B. Guidelines adherence in the treatment of patients with newly
740	[37]	diagnosed type 2 diabates: a historical sohort comparing the use of matformin in Quahas pre and post
749		Canadian Disbates Association environment comparing the use of metrormin in Quebec pre and post-
740	[20]	Canadian Diabetes Association guidennes. <i>DNC Fiedub Serv Kes</i> 2015, 15: 442.
750	[36]	Mitchell BD, EDy EL, Lage MJ. Glycenic control and the first use of oral antidabelic agents among
750	[20]	patients with type 2 diabetes mellitus. <i>Curr Niea Res Opin</i> 2013; 29: 1587–1597.
751	[39]	Vashisht K, Jung K, Shah N. Learning Effective Treatment Pathways for Type-2 Diabetes from a
752	[40]	clinical data warehouse. ANILA. Annu Symp proceedings ANILA Symp 2016; 2016: 2056–2042.
/53	[40]	Fujihara K, Igarashi R, Matsunaga S, et al. Comparison of baseline characteristics and clinical course in
/ 54		Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were
/55	5.4.7	chosen by diabetes specialists as initial monotherapy (JDDM 42). <i>Medicine (Baltimore)</i> 2017; 96: e6122.
756	[41]	Tanabe M, Motonaga R, Terawaki Y, et al. Prescription of oral hypoglycemic agents for patients with
757		type 2 diabetes mellitus: A retrospective cohort study using a Japanese hospital database. J Diabetes
758		Investig 2017; 8: 227–234.
759	[42]	Liu CH, Chen ST, Chang CH, et al. Prescription trends and the selection of initial oral antidiabetic
760		agents for patients with newly diagnosed type 2 diabetes: a nationwide study. Public Health 2017; 152:
761		20–27.
762	[43]	Hully, Stephen B Cummings, Steven R Browner WS, Grady DG, Newman TB. Designing Clinical
763		Research. 2013. Epub ahead of print 2013. DOI: 10.1201/9781003039648-ch2.
764	[44]	Centers for Medicare & Medicaid Services. What's Medicare?, https://www.medicare.gov/ (accessed
765		7 December 2024).
766	[45]	Wang X, Cao Y, Wu Y, et al. The prescription pattern of initial treatment for type 2 diabetes in Beijing
767		from 2011 to 2015. Medicine (Baltimore) 2019; 98: e14370.
768	[46]	Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Cheng AYY. Diabetes
769		Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
770		Can J diabetes 2018; 42 (Suppl: S1–S325.
771	[47]	Araki E, Goto A, Kondo T, et al. Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes
772		Investig 2020; 11: 1020–1076.
773	[48]	Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular
774		disease in patients with diabetes. Eur Heart J 2023; 44: 4043-4140.
775	[49]	Bashier A, Bin Hussain A, Abdelgadir E, et al. Consensus recommendations for management of
776		patients with type 2 diabetes mellitus and cardiovascular diseases. Diabetol Metab Syndr 2019; 11: 80.
777	[50]	Allyhiani M, Kurdi A, Abdulaziz A, et al. Prescribing patterns of antidiabetics in type 2 diabetes and

778		factors affecting them. Saudi Pharm J 2022; 30: 112-119.
779	[51]	Halm EA, Atlas SJ, Borowsky LH, et al. Understanding physician adherence with a pneumonia practice
780		guideline: effects of patient, system, and physician factors. Arch Intern Med 2000; 160: 98-104.
781	[52]	Grustam A, Jovic Vranes A, Soldatovic I, et al. Factors Associated with Utilization of Primary and
782		Specialist Healthcare Services by Elderly Cardiovascular Patients in the Republic of Serbia: A Cross-
783		Sectional Study from the National Health Survey 2013. Int J Environ Res Public Health; 17. Epub ahead
784		of print 10 April 2020. DOI: 10.3390/ijerph17072602.
785	[53]	Qi M, Santos H, Pinheiro P, et al. Demographic and socioeconomic determinants of access to care: A
786		subgroup disparity analysis using new equity-focused measurements. PLoS One 2023; 18: e0290692.
787	[54]	Qiu Y, Li Q, Tang J, et al. Why physicians do not initiate dual therapy as recommended by AACE
788		guidelines: A survey of clinicians in the United States. Diabetes Res Clin Pract 2015; 108: 456-465.
789	[55]	Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss
790		associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care 2012;
791		35: 731–7.
792	[56]	Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol (Lausanne) 2020; 11:
793		191.
794	[57]	Confederat L, Constantin S, Lupaşcu F, et al. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC
795		SULFONYLUREAS. Rev Med Chir Soc Med Nat Iasi 2015; 119: 579–84.
796	[58]	Direção-Geral da Saúde. Abordagem Terapêutica Farmacológica na Diabetes Mellitus Tipo 2 no
797		Adulto. Norma da Direção-Geral da S nº 052/2011 atualizada a 27/04/2015 2015; 1–28.
798	[59]	Riddle MC. Modern Sulfonylureas: Dangerous or Wrongly Accused? Diabetes Care 2017; 40: 629-631.
799	[60]	Hirst JA, Farmer AJ, Dyar A, et al. Estimating the effect of sulfonylurea on HbA1c in diabetes: a
800		systematic review and meta-analysis. Diabetologia 2013; 56: 973-84.
801	[61]	Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes
802		mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement
803		from the American Diabetes Association and the European Association for the Study of Diabetes.
804		Diabetologia 2009; 52: 17–30.
805	[62]	Lalau J-D, Kajbaf F, Bennis Y, et al. Metformin Treatment in Patients With Type 2 Diabetes and
806		Chronic Kidney Disease Stages 3A, 3B, or 4. Diabetes Care 2018; 41: 547–553.
807	[63]	Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus:
808		implications of recent clinical trials. Ann Intern Med 2011; 154: 554–9.
809	[64]	Writing Group Members, Mozaffarian D, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2016
810		Update: A Report From the American Heart Association. Circulation 2016; 133: e38-360.
811	[65]	Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 2022; 12: 7–11.
812	[66]	Hazra NC, Rudisill C, Gulliford MC. Determinants of health care costs in the senior elderly: age,
813		comorbidity, impairment, or proximity to death? Eur J Health Econ 2018; 19: 831-842.
814	[67]	Rodrigues LP, de Oliveira Rezende AT, Delpino FM, et al. Association between multimorbidity and
815		hospitalization in older adults: systematic review and meta-analysis. Age Ageing; 51. Epub ahead of print
816		1 July 2022. DOI: 10.1093/ageing/afac155.
817	[68]	Mahmoud F, Mullen A, Sainsbury C, et al. Meta-analysis of factors associated with antidiabetic drug
818		prescribing for type 2 diabetes mellitus. Eur J Clin Invest 2023; 53: e13997.

Supporting information

- **S1 Table**: Search query on the PubMed (Medline)
- S2 Table: Search query on the Scopus.
- **S3 Table**: Search on the Web of Science.



medRxiv preprint doi: https://doi.org/10.1101/2025.01.22.25320805 preprint (which was not certified by peer review) is the author/fu

It is made avail

Identification of studies via other Additional references identified from: Citation searching (n=4) Full-beat reports assessed for eligibility (n ===4)

Fig 1: Flowchart of study selection processs.